Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast

Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024

The study involved four major activities in estimating the current size of the leukemia therapeutics market. Exhaustive secondary research was done to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.

Primary Research
Several stakeholders such as leukemia drug manufacturers, vendors, distributors and scientists, researchers, oncologist, and doctors from hospitals and clinics were consulted for this report. The demand side of this market is characterized by the significant use of immunotherapies and targeted drugs for leukemia treatment owing to the increasing incidence rate of leukemia across the globe. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

BREAKDOWN OF PRIMARY PARTICIPANTS:

Note 1: C-level primaries include chief executive officers (CEOs), chief operation officers (COOs), and chief financial officers (CFOs). D-level primaries include directors, managers, and heads of departments. Others include sales managers, marketing managers, and product managers.
Note 2: Company tiers are defined by their total revenues. As of 2017, Tier 1: >USD 1 billion; Tier 2: USD 50 million to USD 1 billion; and Tier 3: <50 million.

“To know about the assumptions considered for the study, download the pdf brochure.”

Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the leukemia therapeutics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
The key players in the industry and markets have been identified through extensive secondary research
The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the leukemia industry.

Report Objectives
To define, describe, and forecast the leukemia therapeutics market on the basis of type, application, and region
To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, and opportunities)
To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukemia therapeutics market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
To forecast the size of the market segments in four geographical regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
To track and analyze competitive developments such as product launches, partnerships, expansions, and acquisitions in the leukemia therapeutics market

Scope of the Report
Report Metric Details
Market Size Available for Years 2017–2024
Base Year Considered 2018
Forecast Period 2019–2024
Forecast Units Value (USD)
Segments Covered Leukemia therapeutics market by treatment type, type of leukemia, gender, molecule type, mode of administration, and region
Geographies Covered North America (US, Canada), Europe (Germany, France, UK, and the RoE), APAC (Japan, China, Australia, and the RoAPAC), and the RoW
Companies Covered Major 10 players covered—Novartis (Switzerland), AbbVie (US), Bristol-Myers Squibb (US), F. Hoffmann-La Roche (Switzerland), Sanofi (France), Pfizer (US), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), and Celgene (US)

This research report categorizes the leukemia therapeutics market into the following segments and subsegments:
LEUKEMIA THERAPEUTICS MARKET, BY TYPE OF LEUKEMIA
Acute lymphocytic leukemia (ALL)
Chronic lymphocytic leukemia (CLL)
Acute myeloid leukemia (AML)
Chronic myeloid leukemia (CML)
LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE
Targeted drugs & immunotherapy
Chemotherapy
LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE
Small Molecules
Biologics

LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION
Injectable
Oral
LEUKEMIA THERAPEUTICS MARKET, BY GENDER
Male
Female
LEUKEMIA THERAPEUTICS MARKET, BY REGION

North America
US
Canada
Europe
Germany
UK
France
Rest of Europe
Asia Pacific
China
Japan
India
Rest of Asia Pacific
Rest of the World

Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company
Geographic Analysis: Further breakdown of the European, Asia Pacific, and the Rest of the World segments into their respective countries for this market
Company Information: Detailed analysis and profiling of additional market players (up to 5)
Volume Data: Customization options for volume data (number of units sold) and customization options for volume data (number of tests)
Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market

Related Reports:
INTERVENTIONAL ONCOLOGY MARKET - GLOBAL FORECAST TO 2024
By Product (Radiofrequency, microwave, cryoablation, embolization, guidewires), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis)

STEM CELL ASSAY MARKET - GLOBAL FORECAST TO 2023
By Type (Viability, Purification, Identification), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instruments, Kits), Application (Regenerative Medicine, Clinical Research), End User